

Antonio Merico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/853215/publications.pdf>

Version: 2024-02-01

18
papers

452
citations

933447

10
h-index

996975

15
g-index

18
all docs

18
docs citations

18
times ranked

852
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. , 2016, 35, 22-30.		71
2	Post-acute P300 predicts recovery of consciousness from traumatic vegetative state. Brain Injury, 2009, 23, 973-980.	1.2	64
3	Micro-RNAs in ALS muscle: Differences in gender, age at onset and disease duration. Journal of the Neurological Sciences, 2017, 380, 58-63.	0.6	52
4	Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: implications for clinical therapies. Brain Research, 2000, 854, 35-41.	2.2	46
5	Autonomic dysfunction in the early stage of ALS with bulbar involvement. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 363-367.	2.1	42
6	Effects of combined endurance and resistance training in Amyotrophic Lateral Sclerosis: A pilot, randomized, controlled study. European Journal of Translational Myology, 2018, 28, 7278.	1.7	40
7	300-based brain-computer interface communication: evaluation and follow-up in amyotrophic lateral sclerosis. Frontiers in Neuroscience, 2009, 3, 60.	2.8	37
8	MyomiRNAs Dysregulation in ALS Rehabilitation. Brain Sciences, 2019, 9, 8.	2.3	24
9	Dose-dependent effects of buspirone on behavior and cerebral glucose metabolism in rats. Brain Research, 1995, 677, 213-220.	2.2	15
10	Morphometric correlates of dysarthric deficit in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 464-472.	1.7	13
11	Selective attention impairment in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 236-244.	1.7	11
12	Cerebral metabolic effects of fluoxetine, fluvoxamine, paroxetine and sertraline in the conscious rat. Neuroscience Letters, 2008, 436, 148-152.	2.1	10
13	Efficacy of botulinum toxin type-A and swallowing treatment for oropharyngeal dysphagia recovery in a patient with lateral medullary syndrome. European Journal of Physical and Rehabilitation Medicine, 2017, 53, 798-801.	2.2	8
14	Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine. Brain Research, 2010, 1335, 24-34.	2.2	7
15	Cerebral Metabolic Responses to Clomipramine Are Greatly Reduced Following Pretreatment with the Specific Serotonin Neurotoxin Para-Chloroamphetamine (PCA). Neuropsychopharmacology, 1995, 13, 215-222.	5.4	6
16	Letter to the Editor. Multiple Sclerosis Journal, 2002, 8, 179-179.	3.0	3
17	Integration of a P300 Brain Computer Interface into Virtual Environment. , 2007, , .		3
18	Right fronto-parietal white matter disruption contributes to speech impairments in amyotrophic lateral sclerosis. Brain Research Bulletin, 2020, 158, 77-83.	3.0	0